Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsNewsAboutContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

News

Abrocitinib

(Cibinqo®)

Abrocitinib

Drug updated on 4/18/2024

Dosage FormTablet (oral: 50 mg, 100 mg, 200 mg)
Drug ClassJanus kinase inhibitors
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • For the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Abrocitinib (Cibinqo) is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when the use of those therapies is inadvisable. It demonstrates superiority in efficacy against moderate-to-severe atopic dermatitis and shows significant improvements in Eczema Area Severity Index scores, Investigator Global Assessment scores, and pruritus relief.
  • A total of 18 systematic reviews/meta-analyses provided high-level evidence supporting the use and safety profile of Cibinqo.
  • The majority of studies focused on adult populations with moderate-to-severe atopic dermatitis. There were consistent findings across studies that JAK inhibitors like abrocitinib are effective in both adult and adolescent populations.
  • High-dose upadacitinib appeared as the most effective across various outcomes, while high-dose abrocitinib also showed strong effectiveness but to a slightly lesser extent according to some metrics.
  • In terms of safety concerns associated with this drug class, higher adverse events compared to other systemic treatments have been reported, which include an increased risk of herpes zoster infection, headache occurrence, acne development, and elevated blood creatinine phosphokinase levels among patients using high-dose JAK inhibitors such as abrocitinib.
  • Dupilumab was often used as a benchmark comparator during these studies due to its well-established safety profile despite having intermediate effectiveness compared to the high-dose JAK inhibitors like Cibinqo.
  • Upadacitinib along with Cibinqo might serve particularly effectively for patients seeking rapid symptom control, making them crucial considerations, especially within certain subgroups who prioritize fast symptom relief over long-term effects.
  • The long-term safety profile remains less certain given the relatively short duration of follow-up periods observed by most studies, especially concerning major cardiovascular events or malignancies.

Product Monograph / Prescribing Information

Document TitleYearSource
Cibinqo (abrocitinib) Prescribing Information.2022Pfizer Labs, New York, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. 2023The Journal of Allergy and Clinical Immunology
Oral Janus kinase inhibitors in the treatment of atopic dermatitis: A systematic review and meta‐analysis.2023Skin Health and Disease
Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.2023Heliyon
Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. 2023British Journal of Dermatology
Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. 2023The Journal of Allergy and Clinical Immunology
The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. 2023Journal of the European Academy of Dermatology & Venerelogy
Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis. 2022Dermatologic Therapy
Comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis without topical corticosteroids: Systematic review and network meta-analysis.2022Dermatology and Therapy
Systemic immunomodulatory treatments for atopic dermatitis: Update of a living systematic review and network meta-analysis.2022JAMA Dermatology
Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: A meta-analysis of randomized clinical trials.2022Journal of Demagogical Treatment
Efficacy of biologics and oral small molecules for atopic dermatitis: A systematic review and meta-analysis.2022Journal of Demagogical Treatment
Biological therapies for atopic dermatitis: A systematic review.2021Dermatology
Effectiveness and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis of randomized clinical trials.2021Dermatology Research and Practice
Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: A systematic literature review and network meta-analysis.2021Journal of the European Academy of Dermatology and Venereology
Systematic review on the efficacy and safety of oral Janus kinase inhibitors for the treatment of atopic dermatitis.2021Frontiers in Medicine
Short-term effectiveness and safety of biologics and small molecule drugs for moderate to severe atopic dermatitis: A systematic review and network meta-analysis.2021Life
Efficacy and safety of Janus kinase inhibitors for the treatment of atopic dermatitis: A systematic review and meta-analysis.2021Dermatology
Comparing quality of life outcomes of JAK inhibitors and biological treatments for atopic dermatitis: A systematic review and network meta-analysis.2021Expert Review of Clinical Pharmacology

Clinical Practice Guidelines

Document TitleYearSource
Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.2024Journal of the American Academy of Dermatology